Effect of receptor kinase inactivation on the rate of internalization and degradation of PDGF and the PDGF beta-receptor by unknown
Effect of Receptor Kinase Inactivation on the Rate of 
Internalization and Degradation of PDGF and the PDGF  Receptor 
Alexander Sorkin,* Bengt Westermark,* Carl-Henrik Heldin,* and Lena Claesson-Welsh* 
*  Department of Pathology, University Hospital, Uppsala, Sweden; *  Ludwig Institute for Cancer Research, 
Biomedical Center, Uppsala, Sweden 
Abstract.  The complementary DNAs for wildtype and 
tyrosine kinase-inactivated (K634A) forms of the 
PDGF/3-receptor were expressed in porcine aortic en- 
dothelial cells. We examined the internalization  and 
degradation of ligands and receptors after exposure of 
receptor expressing cells to PDGF-BB, which binds to 
the fl-receptor with high affinity,  and PDGF-AB, 
which binds with lower affinity.  Cells expressing wild- 
type fl-receptors were able to internalize and degrade 
the receptor, as well as the ligand,  after exposure to 
PDGF-BB or -AB.  Cells expressing the kinase-inac- 
tivated mutant receptor also internalized  and degraded 
both receptor and ligand,  but with lower efficiency 
compared with the wildtype receptor cells. The degra- 
dation of either form of receptor was inhibited by 
treatment of the cells with the lysosomotropic drug 
chloroquine.  Exposure of wildtype and K634A recep- 
tor expressing cells to PDGF-AB resulted in a twofold 
slower rate of internalization  of this ligand as com- 
pared with PDGF-BB, whereas the relative rate of 
degradation was similar for the two ligands.  Our data 
indicate that tyrosine kinase activity promotes, but is 
not a prerequisite for, ligand-induced internalization 
and degradation of the ligand-receptor complex. 
A~ 
ajor part of the mitogenic activity in human  serum 
for mesenchymally derived cells, is contributed by 
PDGF (for reviews  see references  20,  36).  PDGF 
consists of disulphide-bonded dimers of homologous A and 
B polypeptide chains, which combine to create the three pos- 
sible isoforms  PDGF-AA, -AB, and  -BB (1, 25, 26).  Two 
PDGF receptor types, which interact  with the three PDGF 
isoforms  with different  affinities,  have been identified  (18, 
19).  The  PDGF  fl-receptor  binds  PDGF-BB  with  high 
affinity  and  PDGF-AB  with  lower  affinity, whereas  the 
PDGF o~-receptor binds all three ligands with high affinity. 
cDNAs for both the or-receptor and the/~-receptor have been 
isolated (7, 9, 15, 28, 43). The receptors belong to the family 
of growth factor receptors equipped with a  ligand-stimu- 
latable tyrosine kinase activity, and they are structurally very 
similar. Their extracellular  parts contain five immunoglobu- 
lin-like domains and their tyrosine kinase domains are split 
into two segments  by the insertion  of ~100 amino acids. 
Binding of ligand has been shown to induce receptor dimer- 
ization,  creating  homo- as well as heterodimers of PDGF 
receptors, most likely through the bivalent interaction of one 
ligand  with two receptor molecules (2,  17, 21, 38). 
Binding of PDGF leads to a rapid internalization  of both 
ligand and receptor (20, 36). Studies based on morphologi- 
cal examinations  have indicated  that  at least the ligand  is 
transferred  to the lysosomes and degraded after internaliza- 
Alexander Sorkin's permanent address is the Institute of Cytology, Academy 
of Sciences  of USSR,  Leningrad 194064,  USSR. 
tion  (30,  35).  However,  in other  studies,  no inhibition  of 
PDGF receptor degradation  was recorded after treatment  of 
ceils with lysosomotropic drugs (23, 27). Studies of the EGF 
receptor have shown that it is rapidly internalized  and de- 
graded in the lysosomes after ligand binding (5, 40); the ef- 
fect of inactivation  of the  nucleotide-binding  lysine resi- 
due in the EGF receptor has been extensively  studied (13, 
14, 22). 
In the present study, we have examined the effects of inacti- 
vation of the tyrosine kinase of the PDGF B-receptor, on the 
internalization  and degradation  of ligand and receptor.  Cells 
expressing  the kinase negative  PDGF fl-receptor  mutant, 
which was created by substituting  the ATP-binding  lysine 
residue in the kinase domain for an alanine  residue,  were 
found  to mediate  internalization  and degradation  of both 
receptor and ligands,  albeit at a slower rate than wildtype 
receptor-expressing cells. 
Materials and Methods 
Cells 
The porcine aortic endothelial (PAE) l cell line (29) was cultured in Ham's 
F12 medium (Gibco/Bethesda  Research Laboratories, Galthersburg, MD), 
supplemented with 10% FCS and 100 U of penicillin/mL These cells lack 
endogeneous expression of the PDGF ~  and B-receptors,  as assessed by 
Northern blot analysis,  immunoprecipitation from metabolically labeled 
cells, as well as radio-receptor assay (41; and data not shown). Complemen- 
1. Abbreviations used in this paper: PAE, porcine aortic endothelial. 
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tor in which the assumed nucleotide-binding lysine residue had been ex- 
changed for an alanine residue (K634A) by site-directed mutagenesis, were 
cloned into the retroviral expression vector pZipNeo (6) and the construc- 
tions were introduced into PAE cells using electroporation, as described 
(38). Selection of  transfected cells was initiated after 48 h by adding Geneti- 
cin ((3418 sulfate; Gibco/Bethesda Research Laboratories) at 0.5 mg/ml to 
the culture medium. G418-resistent colonies were analyzed for binding of 
~2sI-PDGF. 
Antibodies 
The rabbit peptide antiserum PDGFR-3 was generated using a  synthetic 
peptide  corresponding  to  the  murine  PDGF  B-receptor  amino  acids 
981-994; this antiserum reacts in a specific manner with the human PDGF 
B-receptor (8).  The mouse monoclonal antibody PDGFR-B2 was estab- 
lished using purified porcine PDGF receptor preparations as antigen. The 
characteristics of this  antibody have been described (34).  Rhodamine- 
labeled swine anti-rabbit Ig were from DAKOPATTS (Copenhagen, Den- 
mark), rhodamine-labeled goat anti-mouse Ig from Sigma Chemical Co. 
(St.  Louis,  MO),  fluoresceine-labeled goat anti-mouse Ig from Becton 
Dickinson. The secondary antibodies were checked and found not to cross- 
react with Ig from the other species (not shown). 
12~l-PDGF-Binding Experiments 
Recombinant PDGF-BB was purified from a Saccharomyces cerevisiae  ex- 
pression system (31).  PDGF-AB was purified by immobilized metal ion 
affinity  chromatography from PDGF isolated from human platelets (16). 
Alternatively, CHO cells expressing recombinant PDGF-AB were used as 
a  source for purification (32).  PDGF-BB was labeled with 125I using the 
BoRon and Hunter procedure (4) to specific activities of 50,000-70,000 
cpm/ng, and PDGF-AB was labeled using the chloramine T method (24) 
to a specific activity of 150,000 cpm/ng. The iodinated ligands were added 
to cells in MEM supplemented with 20 mM Hepes, pH 7.4, and 0.I% BSA 
(henceforth denoted MEM-BSA). After incubation,  the cell monolayers 
were washed five times using MEM-BSA. In some experiments, the cells 
were thereafter lysed directly in 20 mM Hepes, pH 7.5,  1% Triton X-100, 
10% glycerol, for 30 min at room temperature, to estimate the total amount 
of cell-associated 125I-PDGE To estimate cell surface-bound but not inter- 
nalized ligand, the cells were treated with 0.2 M acetic acid, 0.5 M NaC1, 
pH 2.7, for 5 min on ice, followed by a wash in the same buffer. Both washes 
were combined and analyzed for radioactivity.  This treatment removed 
90-95% of the total cell-associated t25I-PDGF  from cells incubated with 
the ligand at 40C.  After treatment with the acidic buffer, cells were lysed 
in lysis buffer as described above, and analyzed for intracellular radioactiv- 
ity. In certain experiments, milder acidic conditions were used to remove 
cell surface-bound, but not internalized, ligand: cells were treated with 20 
mM sodium acetate, pH 3.7, 150 mM NaCI and 0.2% BSA for 8 rain on 
ice, and then washed with MEM-BSA. After this mild acidic treatment the 
cells were able to bind, internalize, and degrade the ligand with the same 
kinetics as control cells. 
The nonspecific binding of 125I-PDGF was estimated by addition of a 
400-fold excess of unlabeled ligand together with the iodinated material. 
Usually 20-30 % of total cell-associated radioactivity remained, and these 
values were subtracted from the raw data. 
The extent of degradation of iodinated ligand was determined by TCA 
precipitation (10%  TCA for 2 h at 4°C, followed by centrifugation). TCA 
nonprecipitable radioactivity was taken as an estimate of degraded t25I- 
PDGE 
For Scatchard analyses, the cells were incubated in MEM-BSA contain- 
ing 1-2  ng/ml of iodinated PDGF-BB or -AB and 0-400 ng/ml of corre- 
sponding  unlabeled  ligand,  for  2  h  at  2*C,  in  CO2  atmosphere.  The 
monolayers were washed 5 times in MEM-BSA and lysed in lysis buffer as 
described above. The data were analyzed using the RBINDING computer 
program for the linear substraction method (44). 
Immunofluorescence 
PAE cells expressing the wildtype or K634A B-receptor, grown on cover- 
slips, were incubated in the presence of ligand at concentrations and time 
periods as indicated for each experiment. Cells were fixed for 10 min in 
freshly prepared 3.7 % paraformaldebyde in PBS, and thereafter permeabi- 
lized by incubation in MEM-BSA containing 0.15 % saponin (Pierce Chemi- 
cal Co., Rockford, IL). The coverslips were then incubated at room temper- 
ature in the presence of specific antibodies (PDGFR-3 at a dilution of 1:20, 
or PDGFR-B2 at a concentration of 150 ng/ml) followed by secondary anti- 
bodies. In the double labeling experiments, PDGFR-B2 was used at 50 
ng/ml to obtain an intensity of labeling approximately equal to that for 
PDGFR-3. Dilutions and washes were performed in MEM-BSA containing 
0.15%  saponin  (33).  The  coverslips were then  washed  with  PBS  and 
mounted in glycerol-PBS Off), viewed, and photographed using a fluores- 
cence microscope (Nikon Inc., Garden City, NY). 
Metabolic Labeling, Imraunoprecipitation, 
and SDS-PAGE 
Cells were labeled in methionine- and cysteine-free MCDB  104 medium, 
supplemented with [35S]methionine  and [35S]cysteine, each at 100 #Ci/ml 
(1 Ci =  37 GBq; Amersham Corp., Arlington Heights, IL) for 3 h at 37°C; 
the cells were then washed and incubated in MEM-BSA for 30 rain at 37°C. 
The ceils were thereafter incubated in fresh MEM-BSA in the presence or 
absence of ligand at different concentrations and time periods as indicated 
for each experiment. After incubation, the cells were washed three times 
with cold PBS. The cells were lysed and prepared for immunoprecipitation 
by enrichment of the glycoprotein fraction by affinity chromatography on 
Lens culinaris lectin-Sepharose 4B columns (10),  as described (8).  Im- 
munoprecipitations were performed as described (8), using PDGFR-3 se- 
rum followed by adsorbtion to protein A-Sepharose, or purified PDGFR-B2 
coupled to Sepharose 4B. 
SDS-PAGE was carried out in 5-10%  gradient slab gels, according to 
Blobel and Dobberstein (3). Chemicals were from Bio-Rad Laboratories 
(Cambridge, MA). Gels were prepared for fluorography by making in Am- 
plify (Amersham Corp.), dried, and exposed to Hyperfilm MP (Amersham 
Corp.). 
Chloroquine Treatment 
Chloroquine (Sigma Chemical Co.) in MEM-BSA was added to a final con- 
centration of 100/zM at specified timepoints. 
Results 
Binding of  PDGF-BB and -AB to Porcine 
Aortic Endothelial Cells Expressing l~ldtype and 
K634A PDGF  B-Receptors 
PAE cells expressing wildtype PDGF B-receptor or B-recep- 
tor mutated at the ATP- binding lysine residue (K634A) were 
generated  by transfecting  PAE  cells  with  the  appropriate 
cDNAs cloned into the expression vector pZipNeo (6). The 
tyrosine kinase-inactivated PDGF B-receptor was previously 
shown to be unable to mediate ligand-induced receptor auto- 
phosphorylation, actin reorganization (41), and mitogenesis 
(12).  Scatchard  analyses  were performed  to  estimate  the 
number of PDGF-BB and PDGF-AB binding sites and appar- 
ent affinities for wildtype receptor expressing cells and for 
two  independendy  isolated  cell  lines  expressing  K634A 
receptors.  As seen in  Fig.  1,  PDGF-BB bound with high 
and approximately  similar apparent  affinities to wildtype, 
K634A-2, and K634A-6 B-receptor-expressing cells (Fig. 1, 
A, C, and E). In each case, PDGF-AB bound with 4-10-fold 
lower apparent affinity (Fig.  1, B, D, and F). These record- 
ings are consistent with earlier estimations for the wildtype 
receptor expressed in CHO cells (39). 
The estimated number of binding sites for PDGF-AB as 
well  as  PDGF-BB  was  slightly  lower  on  K634A-2  and 
K634A-6 (35,000--40,000 mol wt) receptor expressing cells 
as compared with wildtype receptor-expressing cells (45,000-- 
55,000 mol wt). For each cell type, the apparent number of 
binding  sites  was  similar  for  PDGF-AB  and  PDGF-BB. 
However, the lower affinity recorded for PDGF-AB makes 
the estimation of binding sites for this ligand more difficult 
to evaluate. 
The Journal  of Cell Biology,  Volume 112, 1991  470 L 
Z 
A 
wt 
POGF-BB 
200 ~IM 
4*  •  • 
100 
C 
K634A-6 
PDGF-BB 
100 "  ~  I"  KD'O.$71nM 
E 
K634A-2 
PDGF-BB 
10050 .O ~  KD~O.682nM 
.  'i  2O  40  6O  80 
wt 
•  PDGF-AB 
o~e t  KD: 2.76  nM 
K634A-6 
PDGF-AB 
•  Ko ~  2.44  n  M 
K634A-2 
POGF-AB 
Ko : 2.94  nM  0 
20  40  60  80 
B 
30 
|0 
10 
O 
30 
20 
10 
30 
20 
10 
60UNO (fmol/10acells) 
Figure 1. Scatchard analysis of PDGF-BB (A, C, and E) and PDGF- 
AB (B, D, and F) binding to PAE cells expressing wildtype (A and 
B),  K634A-6 (C and  D),  and  K634A-2 (E  and  F)  PDGF  /~- 
receptors. 
Internalization and Degradation of PDGF-BB 
and PDGF-AB 
To examine the rate of endocytosis of bound ligand,  wild- 
type,  K634A-2,  and  K634A-6  receptor-expressing  cells 
were incubated  in the  presence of 1 ng/ml of ~2sI-PDGF- 
BB or t25I-PDGF-AB  at 37°C for various time periods. The 
cell cultures were washed with an acidic buffer to release 
surface bound ligand and the cells were then solubilized (Fig. 
2 A). Since internalized ligand is protected from the acid and 
released only after solubilization of the cells, this procedure 
makes it possible to distinguish between cell surface and in- 
ternalized ligand.  Under the conditions used,  '~10% of the 
cell surface receptors were occupied and this number did not 
change significantly with time. Also, the number of available 
binding sites remained constant, since the concentration of 
ligand was too low to appreciably downregulate the surface 
receptors. Therefore, the increase in ratio between internal- 
ized and surface bound ligand should reflect the relative rate 
of internalization under steady-state conditions (42). The in- 
ternalization rate of t25I-PDGF-BB  as well as of '2sI-PDGF- 
AB was similar in K634A-2 and K634A-6 cells (not shown) 
and slower than in wildtype cells.  In all types of cells, the 
internalization of tE~I-PDGF-BB occurred faster than that of 
~25I-PDGF-AB. Similar  differences in  rates  of internaliza- 
tion were seen when cells were preincubated in the presence 
of labeled ligands for 1 h at 4°C to load the receptors with 
ligand, before incubation at 37°C  (data not shown). 
The relative rates of ligand degradation were measured 
by  incubating  wildtype,  K634A-2,  and  K634A-6  recep- 
tor-expressing cells with 2  ng/ml of ~2sI-PDGF-BB or ~2~I- 
PDGF-AB for 5 min at 37°C,  followed by 90 min at 17°C, 
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Figure 2.  (A) Estimation of the relative rate of internalization  of 
PDGF-BB and PDGF-AB, by cells expressing wildtype and K634A 
receptors. Cells with wildtype (e,-) and K634A-6 (o,A) receptors 
were incubated in the presence of 1 ng/ml of ~2sI-PDGF-BB  (o,e), 
or 125I-PDGF-AB (,x,A) for the indicated periods of time, washed 
with an acidic buffer to release surface-bound ligand, and solubi- 
lized to determine the amount of intracellular  ligand. The rate of 
internalization  is expressed as the ratio between internalized and 
surface-bound ligand. (B) Estimation of the relative rate of degra- 
dation  of PDGF-BB  and  PDGF-AB,  by  cells  expressing  wild- 
type and K634A receptors.  Cells were incubated with 2 ng/ml of 
~25I-PDGF-BB or ~2sI-PDGF-AB  for 5 min at 37°C, followed by 90 
min at 17°C; unbound ligand was then removed by washing. The 
cells were incubated at 17°C for 90 min and thereafter  at 37°C 
for  the  time  periods  indicated.  The  amount  of  intracellular 
z25I-PDGF-BB and ~2sI-PDGF-AB  was determined  by solubilizing 
the ceils, and degraded  ligand was estimated by determining the 
amount of TCA-nonprecipitable radioactivity in the medium.  The 
rate of degradation is expressed as the ratio between degraded and 
intracellular  ligand. 
to allow internalization to the endosomal, but not lysosomal 
compartment; ceils were then washed to remove unbound 
ligand, and further incubated for 90 min at 17°C.  Degrada- 
tion was initiated by increasing the incubation temperature 
to 37°C (Fig. 2 B). The kinetics of ligand degradation was 
expressed as the ratio between IV_A-nonprecipitable radioac- 
tivity in the medium and intracellular radioactivity. The rate 
of  ligand  degradation  was  similar  for  the  K634A-2  and 
K634A-6 receptor-expressing cells (not shown) and slower 
than  for wildtype  receptor  cells,  irrespective of whether 
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Figure 3.  Downregulation of 
wildtype  and  K634A recep- 
tors.  Cells  expressing  wild- 
type (o,A) or K634A-6 (o,zx) 
receptors were incubated for 
2 h at 37°C in the presence of 
0-200  ng/ml of  PDGF-BB 
(O,o)  or  0--400 ng/ml  of 
PDGF-AB (A,A). Cells were 
washed with an acidic buffer 
to release bound but not inter- 
nalized ligand; the binding of 
t2sI-PDGF-BB was  then  de- 
termined. 
PDGF-BB or PDGF-AB was used. 
The relative number of cell surface receptors on wildtype 
or K634A-6 receptor cells remaining after 2 h incubation at 
37°C with various concentrations of PDGF-BB or PDGF- 
AB, was estimated through binding of '2q-PDGF-BB after a 
mild  acidic  wash  and  transfer to  4°C.  On  wildtype and 
K634A-6 receptor cells exposed to saturating concentrations 
of  PDGF-BB,  30-40%  of  the  binding  sites  remained, 
whereas PDGF-AB-treated cells had 70-80%  of the sites 
available on untreated cells (Fig.  3).  The binding sites re- 
maining after PDGF-AB treatment could be downregulated 
by exposure of the cells of PDGF-BB (not shown). 
Internalization and Degradation of Wildtype 
and 1(634,4 PDGF  B-Receptors Examined by 
Immunofluorescence Staining 
Internalization and degradation of PDGF ~-receptors was ex- 
amined through fluorescence microscopy using the ~-recep- 
tor-specific monoclonal antibody PDGFR-B2 (34). This an- 
tibody reacts with the external domain of the B-receptor. It 
mediates a weak and diffuse cell surface staining when used 
at higher concentrations. When the antibody is used at very 
low concentrations on ligand-stimulated cells, patchy stain- 
ing is observed (TingstrSm, A., manuscript in preparation), 
but only after detergent treatment of the cells. Consequently, 
with the antibody concentrations used in the experiments de- 
scribed below  (100-150  ng/ml),  only clustered receptors, 
presumably  concentrated  in  endosomes/lysosomes,  were 
stained. 
To follow internalization and degradation of receptors, the 
wildtype, K634A-2, and K634-6 receptor cells were exposed 
to saturating concentrations of either PDGF-BB or PDGF- 
AB for 30 min at 370C,  and processed for immunostaining. 
Both PDGF-BB (100 ng/ml) (Fig. 4 a) and PDGF-AB (400 
ng/ml) (Fig. 4 c) induced the appearance of brightly stained 
vesicles in the cell periphery and perinuclear region in cells 
expressing wildtype receptors. Although a similar pattern of 
staining was displayed, the brightness of staining and num- 
ber of fluorescent structures were somewhat lower in ceils 
expressing K634A-6 receptors, irrespective of ligand used 
(Fig. 4, e and g). The fluorescent staining disappeared from 
cells with wildtype receptors when the incubation period in 
the presence of ligand was extended to 2 h (Fig. 4, b and d), 
whereas  some  staining  remained  in  cells  with  K634A-6 
receptors after exposure to ligand for the same time (Fig. 4, 
fand h). Complete disappearance of K634A-6 receptors was 
attained by 4 h of incubation in the presence of ligand (data 
not shown). The K634A-2 cell line displayed a pattern and 
kinetics of disappearance of staining indistinguishable from 
that for the K634A-6 cells (not shown). 
Chloroquine-induced Block in 
Degradation of V~ldtype  B-Receptors Visualized 
by Immunofluorescence Staining 
Wildtype/~-receptor cells were incubated in the presence of 
100 ng/ml of PDGF-BB for 5 min at 37°C and then for 3 h 
at room temperature. Chloroquine was added to the medium 
15 min before the end of the incubation period.  Unbound 
ligand was then washed away, and the cells were further in- 
cubated for 2 h at 37°C, in the continued presence of 100 ~M 
chloroquine. At this point, the cells were fixed and treated 
for immunofluorescence using the PDGFR-B2 antibody, to 
stain intracellularly located/3-receptors. 
At room temperature, PDGF-BB induced internalization 
and accumulation of wildtype B-receptors within endosome- 
like structures (Fig. 5 a). The following incubation at 37°C 
led to disappearance of the staining, due to degradation of 
the molecules (Fig. 5 b). Under the same conditions, but in 
the presence of chloroquine, a considerable accumulation of 
staining was seen (Fig. 5 c). The chloroquine-induced block 
of receptor degradation could also be seen when ceils were 
stained with the antibody PDGFR-3 (8), which recognizes 
the intracellular domain of the ~-receptor. In fact, the stain- 
ing mediated by PDGFR-3 colocalized with that seen with 
PDGFR-B2,  which recognizes the extracellular domain of 
the ~-receptor (Fig. 5, d and e). A similar block in degrada- 
tion was  seen also when cells were incubated with either 
PDGF-BB and PDGF-AB at 37°C, without prior preincuba- 
tion at room temperature, or when preincubation was per- 
formed at 4°C. The degradation of/~-receptors in K634A-2 
and K634A-6 cells were inhibited to the same extent as in 
wildtype cells by  chloroquine after ligand  exposure (not 
shown). Furthermore, inhibition of degradation of wildtype, 
K634A-2 and K634A-6 receptors was also seen after treat- 
ment of the cells with monensin, as well as other amines (not 
shown). 
Turnover of  PDGF  B-Receptors in Metabolically 
Labeled Cells 
Ligand-induced internalization and degradation of PDGF 
/3-receptors was  further followed by  immunoprecipitation 
from metabolically labeled wildtype, K634A-2, and K634A-6 
Figure 4. PDGF E-receptor immunofluorescence staining in cells with wildtype and K634A receptors after exposure to PDGF-BB and 
PDGF-AB. PAE cells with wildtype (a-d) and K634A (e-h) receptors were incubated with 100 ng/ml of PDGF-BB (a, b, e, and f) or 
400 ng/ml of PDGF-AB (c, d, g, and h) for 30 min (a, c, e, and g), or 120 min (b, d, f, and h) at 37°C. The cells were fixed  and stained 
using PDGFR-B2. Arrows show the accumulation of B-receptors in juxtanuclear  area. Bar, 10 tzm. 
The Journal of Cell Biology,  Volume 112, 1991  472 Sorkin et al. Internalization of PDGF B-receptor  473 Figure 5.  PDGF/~-receptor immunofluorescence staining of cells expressing wildtype receptors treated with chloroquine after exposure 
to PDGF-BB. The cells were incubated in the presence of 100 ng/ml of PDGF-BB for 5 min at 37°C, and further incubated for 3 h at 
17°C  (a). Chloroquine (100 ~M) was added 15 min before the end of the 3 b incubation, thereafter the cells were transferred to 37°C 
for a continued 2-h incubation in the presence (c, d, and e) or absence (b) of 100 ~M chloroquine. The cells were fixed and processed 
for immunofluorescence staining using PDGFR-B2 (a-d) or PDGFR-3 (e). Arrows show colocaiization of staining with PDGFR-B2 and 
PDGFR-3. Bar,  10/~m. 
The Journal  of  Cell  Biology, Volume  112, 1991  474 Figure 6. Turnover of B-receptors in metabolically labeled cells with wildtype and K634A receptors.  Cells with wildtype (lanes a-j) and 
K634A-6 (lanes k-t) receptors were cultured in the presence of [35S]methionine and [35S]cysteine for 3 h and then in MEM-BSA for 30 
min at 37°C. Samples were either removed for processing,  (p), (lanes a and k) or transferred to fresh medium, containing an excess of 
unlabeled methionine and cysteine ("chase" medium) without ligand (lanes b-d and l-n) or supplemented with  100 ng/ml of PDGF-BB 
(lanes e-g and o-q) or 400 ng/ml of PDGF-AB (lanes h-j and r-t).  Chase periods  in the absence or presence  of ligands were 30 min 
(c/; lanes b, e, h, l, o, and r),  120 min (c2; lanes c,f, i, rn, p, and s), and 240 rain (c3; lanes d, g,j, n, q, and t). Cell samples were 
processed for immunoprecipitation using PDGFR-3. Immunoprecipitated  material were analyzed by SDS-gel electrophoresis and fluorog- 
raphy. The relative migration  rates of the mature (190 kD) and precursor (160 kD) forms of the B receptor are indicated. 
cells.  The cells were cultivated in the presence of [3sS]me- 
thionine and  [35S]cysteine  for 3  h,  whereafter the medium 
was  changed  to  MEM-BSA;  after  an  additional  30  min, 
ligands  were  added.  Four  times  higher  concentrations  of 
PDGF-AB  (400  ng/ml)  than  PDGF-BB  (100  ng/ml)  were 
used to compensate for the differences in receptor binding 
affinities. PDGF B-receptors were immunoprecipitated from 
solubilized cells using the B-receptor specific peptide antise- 
rum  PDGFR-3.  From  all  three  cell  lines,  this  antiserum 
precipitated  two  components  of  190  and  160  kD,  corre- 
sponding to the mature and the precursor forms of the recep- 
tors, respectively (8).  The intensity of the immunoprecipi- 
tated 190-kD band was substantially reduced when wildtype 
(Fig. 6, lanes e, f, and g) receptor expressing cells were ex- 
posed to PDGF-BB. As seen from densitometric scanning of 
the fluorogram (Fig. 7), the amount of immunoprecipitated 
190-kD band from wildtype receptor cells was reduced to 
close to zero after 1 h exposure to PDGF-BB. Exposure of 
wildtype receptor cells to PDGF-AB also cause a disappear- 
ance of the mature receptor band, albeit with a slower rate 
(Fig.  6,  lanes h,  i, and j).  In the plot shown in Fig.  7, the 
intensity of the B-receptor band after ligand stimulation is 
expressed as percent of that for the B-receptor band from un- 
treated cells. Thus, although the effect of PDGF-AB was less 
pronounced, it did increase the turnover rate of the B-recep- 
tor in a  ligand-specific way. 
The rate of degradation of the K634A receptor was slower 
than that of the wildtype receptor; 4 h exposure to PDGF-BB 
was needed to cause complete disappearance of the 190-kD 
band (Fig. 6, lanes o, p, and q show that K634A-6 cells). An 
even slower rate of disappearance of the 190-kD component 
was seen when PDGF-AB was added to K634A receptor ex- 
pressing cells (Fig. 6, lanes r and s, and t show the K634A-6 
cells). The rate of ligand-induced receptor turnover was very 
similar in the two cell lines expressing the mutated B-recep- 
tor; the plot shown in Fig. 7 is therefore averaged from sev- 
eral experiments using K634Ao2  or K634A-6 cells. 
The  simultaneous  expression  of the  PDGF  or-receptor 
changes the efficiency of PDGF-AB induced downregulation 
of the PDGF B-receptor. Fig. 8 shows immunoprecipitation 
from metabolically labeled, ligand-stimulated human fore- 
100 
so 
0 
0 
0. 
0  1  2  3  4 
Hours 
Figure  7. Densitometric scanning 
of  fluorograms  of  the  mature 
190-kD form of the  B-receptor. 
Scanning was performed  on flu- 
orograms  showing  immunopre- 
cipitations  from cells expressing 
wildtype  (e,a) or K634A (o,zx) 
receptors,  incubated in the pres- 
ence  of  100  ng/ml  PDGF-BB 
(o,e)  or  400  ng/ml  PDGF-AB 
(A,a) for the time periods  indi- 
cated.  The data for the K634A-2 
and  K634A-6 cells  were  corn- 
bined.  Each point  represents an average of at least three experi- 
ments performed as described in Fig. 6. The intensity of the B-re- 
ceptor band in ligand-treated cells is expressed as % of that in the 
corresponding untreated  samples. The intensity of the B-receptor 
band in the untreated samples decreased from 100% in lanes a and 
k in Fig.  3, to 52 % in lanes d and n. 
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fibroblasts. Human foreskin fibroblasts, AG1523, which expresses 
both types of PDGF receptors, were metabolically labeled for 3 h, 
as described for PDGF/3-receptor-expressing PAE cells in Fig. 6. 
Samples were either removed for processing (lane a) or transferred 
to fresh medium in the absence of ligand (lane b) or in the presence 
of  either 50 ng/ml of  PDGF-BB (lane c), 100 ng/ml PDGF-AB (lane 
d).  All  samples were processed for immunoprecipitation using 
PDGFR-3. Immunoprecipitated material was analyzed by SDS-gel 
electrophoresis and fluorography. The relative migration rates of 
the mature:(180  kD) and precursor (160 kD) forms of  the E-receptor 
are indicated. The apparent molecular weight of the mature form 
of the PDGF/~-receptor in human foreskin fibroblasts is 180 kD 
(44) rather than 190 kD, probably due to differences in glycosy- 
lation. 
skin fibroblasts. In this cell line, which expresses both types 
of PDGF receptors, a complete down regulation of the B-re- 
ceptor band was seen after 1 h exposure of the cells to 50 
ng/ml of PDGF-BB or 100 ng/ml of PDGF-AB. 
Discussion 
PAE  cells,  which  lack endogeneous expression of PDGF 
receptors, were used for expression of the wildtype and tyro- 
sine kinase-inactivated form of the PDGF ~-receptor. The 
characteristics of the wildtype B-receptor expressed in PAE 
cells were very similar to those described for the endogene- 
ous B-receptor in human foreskin flbroblasts, as well as the 
B-receptor expressed in CHO cells after transfection (39; and 
data not shown). The turnover rates of the wildtype and mu- 
tated B-receptors in PAE cells, in the absence of ligand, were 
similar (4 h; Fig. 6). The small but significant differences in 
the efficiency of ligand-mediated internalization and degra- 
dation between the wildtype receptor expressing cells and 
two  independent isolates  of cells  expressing  the  mutated 
receptor, can therefore not be ascribed to differences in cel- 
lular constitutive turnover rates. 
The  discrete  impairment  in  the  rate  of ligand-induced 
downregulation noted for the mutated receptor indicates that 
there is no absolute requirement for kinase activity in en- 
docytosis of the PDGF B-receptor complex. A slower turn- 
over rate was also seen for both the wildtype and K634A 
receptor after exposure to  PDGF-AB,  as  compared  with 
PDGF-BB.  In  human  foreskin fibroblasts,  which  express 
both types of PDGF receptors, PDGF-AB efficiently  induced 
down  regulation  of the  B-receptor (Fig.  8).  The  ligand- 
dependent delay in PAE cells appeared to be in the rate of 
internalization and not in the rate of degradation (Fig. 2, A 
and B) at least when the ligand itself was examined. It is pos- 
sible that the delay seen when using PDGF-AB is a conse- 
quence of a suboptimal conformational state of the receptor 
molecule induced by this ligand, which binds to the B-recep- 
tor with lower affinity, as compared with PDGF-BB. It has 
recently been shown that PDGF B-receptors dimerize as a 
consequence of ligand binding, before and possibly a prereq- 
uisite for activation of the tyrosine kinase domain (2, 21). 
PDGF-AB has been shown to induce formation of hetero- 
dimers of or- and B-receptor (17, 38), in which the A-chain 
would be bound to the u-receptor, and the B-chain to the/~-re- 
ceptor. If no a-receptors are available to bind the A-chain, 
as  is  the  case in  PAE cells,  B-receptors that  have bound 
PDGF-AB  might  remain  in  a  monomeric  configuration. 
Such  ligand-receptor complexes may be  internalized less 
efficiently compared to dimeric receptor complexes, with or 
without activated tyrosine kinase domains. 
Our data on the block in degradation induced by treatment 
of cells with chloroquine, indicate that the two ligands, as 
well  as  the  wildtype  and  K634A  receptors  follow  the 
lysosomal pathway for degradation, eliminating the need to 
postulate a novel pathway for degradation of the PDGF B-re- 
ceptor (23,  27).  Receptors which accumulated after treat- 
ment of cells with chloroquine could be detected by im- 
munofluorescence staining  using  two different antibodies, 
directed  against  the  extra-  or  the  intracellular  domains, 
respectively  (Fig.  5).  However,  in  agreement  with  data 
reported  by  others  (23,  27),  we  were  unable  to  see  a 
chloroquine-mediated block in degradation of B-receptors, 
using immunoprecipitation from metabolically labeled cells 
as an assay,  irrespective of which antibody was used (not 
shown). The reason for the discrepancy between the results 
of the two assays is not clear. However, it is possible that ac- 
cumulated receptors might have become less soluble, e.g., 
through association with the detergent insoluble cell frac- 
tion, which in our procedure was removed by centrifugation 
from the lysate, before immunoprecipitation. 
Studies addressing the question of the role of tyrosine ki- 
nase activity in endocytosis have been performed on other 
growth factor receptors with tyrosine kinase domains. In the 
case of the EGF receptor, inactivation of the kinase resulted 
in a  receptor that failed to undergo downregulation in re- 
sponse to ligand, such that the mutant receptor in the presence 
of EGF retained the half-life of the unoccupied wild-type 
receptor. There are conflicting interpretations regarding the 
mechanisms  involved, however. Whereas  Honegger et al. 
(22) and Felder et al. (13) reported that their EGF receptor 
kinase mutant expressed in NIH 3T3 cells was internalized, 
but escaped degradation and recycled back to the cell sur- 
face; Glenney et al. (14) failed to record any internalization 
of their mutant, expressed in B82 or CHO cells. Analysis of 
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3T3 cells  revealed that the ligand-induced downregulation 
was abolished,  but the mechanisms involved were not ana- 
lyzed (11). On the other hand, downregulation and receptor 
degradation after ligand binding was recorded for the tyro- 
sine kinase-inactivated insulin receptor (37). 
Several mechanisms could account for the discrete impair- 
ment in efficiency in downregulation and receptor degrada- 
tion which we report for the PDGF/g-receptor tyrosine ki- 
nase mutant expressed in PAE cells. It is possible that the 
rate of endocytosis can be modulated by receptor mediated 
tyrosine  phosphorylation of  key molecules in the endocytotic 
machinery.  Alternatively, the observed  slower endocytotic 
rate of the tyrosine kinase-inactivated receptor  may be due 
to an inefficient sorting to the lysosomal route after internali- 
zation. A fraction of  the internalized receptors might recycle 
back to the cell surface and thereby escape degradation. Fu- 
ture studies will be aimed at examining whether the kinase- 
inactivated PDGF 3-receptor  undergoes recycling. 
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